Slides
Page 1
November 2, 2026 2026 Third Quarter Financial Results Redefining Possibilities in Rare Disease
Page 2
2 Forward-Looking Statements and Non-GAAP Financial Measures Transforming Lives. Redefining Possibilities. This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to: the company’s growth prospects and future financial and operating results, including the company’s 2026 financial guidance and the company’s expectations related thereto; the company’s advancement of pipeline programs and the timing of development activities, regulatory activities, approvals, and submissions related thereto; the company’s development, regulatory and commercialization strategy; the company’s capital allocation and corporate development strategy; the commercial potential of the company’s products; the company’s views and expectations relating to its patent portfolio; and other statements that are not historical facts. These forward- looking statements are based on the company’s current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Epidiolex/ Epidyolex, Ziihera, Modeyso, Zepzelca and other lead marketed products; effectively launching and commercializing the company’s other products and product candidates; the successful completion of development and regulatory activities with respect to the company’s product candidates; obtaining and maintaining adequate coverage and reimbursement for the company’s products; the time-consuming and uncertain regulatory approval process; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the company’s business operations and financial results; protecting and enhancing the company’s intellectual property rights and the company’s commercial success being dependent upon the company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the company’s products and product candidates; complying with applicable U.S. and non- U.S. regulatory requirements; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired products, product candidates and businesses; the company’s ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the company’s cash flows and capital resources; the company’s ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; fluctuations in the market price and trading volume of the company's ordinary shares; and other risks and uncertainties affecting the company, including those described from time to time under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission filings and reports, including the company's Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and future filings and reports by the company. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. GAAP, the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation that exclude certain items that are included in the most directly comparable GAAP financial measures, as detailed in the reconciliation tables included in the Appendix hereto. The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the company’s financial information prepared in accordance with GAAP, can enhance investors’ and analysts' ability to meaningfully compare the company’s results from period to period and to its forward-looking guidance, and to identify operating trends in the company’s business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company’s financial performance. The company’s management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company’s business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by the company in this presentation and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
Page 3
Renee Gala President and Chief Executive Officer 3 Introduction and Overview 0
Page 4
4 Strong Execution Across Franchises Drives 2026 Revenue Guidance Increase 4 3Q26 Execution Highlights Upcoming Milestones Financial Strength Strong balance sheet: • Cash4 at end of 3Q26: $2.9B • YTD5 operating cash flow: $1.3B Robust 3Q26: • Record quarterly revenues of $1.24B (+10% YoY) • Raised full-year 2026 revenue guidance • Raised $1.25B from exchangeable senior notes • Closed $820M Actio acquistion3 Commercial: • Total Revenues (+10% YoY) • Oncology (+35% YoY) • Xywav (+12% YoY) • Ziihera launched in HER2+ 1L GEA R&D: • Final analysis from Phase 3 HERIZON-GEA-01 presented at ESMO1 • April 16, 2027 PDUFA date for Epidiolex cannabidiol oral capsule formulation2 • Strengthened epilepsy portfolio acquiring ABS-1230 (JZP6979) for KCNT1+ epilepsy • ABS-1230 (JZP6979) patient data to be presented at a medical meeting in 4Q26 • Modeyso ACTION study data 1H27 • EmpowHER-BC-303 trial enrolling, data expected late 2027 / early 2028 • Robust zanidatamab development program continues to progress • Continued opportunities to drive value and growth through strategic business development 1Shitara et al., ESMO 2026; 2Cannabidiol capsule formulation, if approved, for use within Epidiolex’s existing approved indications (LGS, DS or TSC); 3Actio Biosciences, Inc. (“Actio”) acquisition closed on September 15, 2026 for $820M upfront net of cash acquired and $500M in potential approval and sales milestones; 4Cash includes cash equivalents and investments as of September 30, 2026; 5For the nine months ended September 30, 2026.
Page 5
5 Actio Acquisition: Building on Success in Rare Epilepsies Jazz completed Actio acquisition, expanding rare epilepsies portfolio • Strong strategic fit that is complementary to Jazz’s existing development and commercial expertise in rare pediatric epilepsy • Adds ABS-1230 (JZP6979 ), a clinical-stage first-in-class genetic precision KCNT1 inhibitor • KCNT1+ epilepsy is a genetic DEE affecting ~2,500 U.S. patients1 with no FDA approved therapies ABS-1230 (JZP6979) has potential to address a significant unmet need • Demonstrated meaningful seizure reductions in early proof-of-concept trials in children with KCNT1+ epilepsy • Received FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations and accepted into the Rare Disease Evidence Principles process • Ongoing registrational Phase 1b/2a KYRON trial2 to support potential NDA • Initial patient data to be presented at medical meeting in 4Q26 Transaction Terms • Includes $820M3 upfront payment and up to $500M in potential approval and sales milestones 1Data on File; 2NCT07600736; 3Net of cash acquired. +
Page 6
Sam Pearce Executive Vice President and Chief Commercial Officer 6 Commercial Performance
Page 7
7 Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity 1Approximate active Xywav patients exiting quarter; 2Based on 3Q26 Xywav net product sales; 3Rare sleep franchise includes Xywav, Xyrem, and high-sodium oxybate AG royalties. 10,725 10,950 11,075 11,275 11,375 4,950 5,225 5,525 5,850 6,175 3Q25 4Q25 1Q26 2Q26 3Q26 NET ACTIVE XYWAV PATIENTS1 NarcolepsyIH • Xywav revenue grew 12% YoY; continued momentum with 425 net patient adds in 3Q26 • Benefits of highly efficacious and safer treatment option due to reduced sodium content along with an individualized dosing regimen continue to resonate with patients and HCPs Narcolepsy • Xywav remains the #1 branded treatment for narcolepsy2 Idiopathic Hypersomnia • Continued positive momentum from investments to further build the IH market driving 325 IH net patient adds in 3Q26 Rare sleep3 franchise: • Total rare sleep3 revenue of $552M in 3Q26 • In 2026, now expect total rare sleep3 revenue of $2.125 to $2.175B
Page 8
8 Epidiolex: Development Opportunities for Durable Growth 1Based on 3Q26 Epidiolex net product sales; 2Cannabidiol capsule formulation, if approved, for use in Epidiolex’s currently approved indications: LGS, DS, TSC; 3Eeghen, AM, Thiele, EA, et al. Poster presented at: American Epilepsy Society 2024 Annual Meeting, December 6-10, 2024. Los Angeles, CA; 4Wrobel, N. Poster presented at: American Academy of Neurology 2025 Annual Meeting, April 5-9. San Diego, CA. Epidiolex is the #1 branded epilepsy treatment1 • Revenues of $295M in 3Q26 • Consistent demand growth in 3Q26 with lower inventory build due to wholesaler buying patterns; 3Q25 benefited from lower gross-to-net deductions Growth opportunities: • Expanded Epidiolex development opportunities with multiple new clinical trials • PDUFA date of April 16, 2027, for cannabidiol oral capsule formulation2, designed to help broaden utilization and increase flexibility for patients • Further data generation, including beyond-seizure benefits from the EpiCom3 study in TSC and nurse-reported responses from the BECOME4 caregiver survey in long-term care facilities • JazzCares suite of services including the Nurse Navigator program helps support patients and families through their treatment journey $218 $252 $303 $287 $250 $292 $295 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 Net product sales ($ in millions) Quarterly Net Product Sales
Page 9
9 Now Approved in 1L HER2+ mGEA Goal: Establish Ziihera as HER2-Targeted Agent of Choice in 1L HER2+ GEA 1Based on Jazz market research; 2Month-over-month, reflecting the first full month of launch in September 2026. Jun-26 Jul-26 Aug-26 Sep-26 Promising Early Demand Following August 25, 2026 Approval New ordering accounts Average demand vials per selling day 3X Increase ~40% Increase Clinical Education & Differentiation Accelerated Market Access Commercial & Field Launch Execution Seamless Patient Experience 79% intent to prescribe1 43% unaided awareness1 Secured broad access and reimbursement with preferred placement on the largest oncology pathway 3x increase in new accounts ordering, 80% in the community2 ~40% increase in daily demand2 Nurse educators and patient starter kits support a seamless start on therapy 1st month of launch
Page 10
10 Zanidatamab: Updated Peak Sales Opportunity of $3-$5B Zanidatamab: Updated Peak Sales Opportunity of $3-$5B Drivers of Peak Sales Increase: • Approvals in BTC and GEA, derisked investments in existing studies • Multiple ongoing registrational trials in 1L BTC, Pan-Tumor, and mBC • Additional registrational trials planned in CRC, NSCLC, early gastric cancer, early BC, and with novel combinations in BC, including TKIs Biliary Tract Cancer Breast Cancer Gastroesophageal Adenocarcinoma Broad Potential • Ongoing registrational Pan Tumor trial (DiscovHER-Pan-206) • Colorectal cancer • Non-small cell lung cancer • Combinations with novel agents Other HER2- Expressing Cancers $3-$5 billion peak sales opportunity New Standard of Care in 2L BTC Phase 3 in 1L BTC (HERIZON-BTC-302) New Standard of Care in 1L HER2+ GEA Opportunity in early GEA Ongoing Phase 3 trial in mBC (EmpowHER-BC-303) Opportunity in early BC (EmpowHER-BC-208) Opportunity with novel combinations in BC, including TKI combinations
Page 11
11 Modeyso: First and Only FDA-approved Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma $11 $61 3Q25 3Q26 2 ~$200M in sales since launch in 3Q251 Net product sales ($ in millions) Strong Initial Uptake and Early Launch Success • $61M in 3Q26 net product sales • ACTION trial readout 1H27 could drive earlier-line use Continued Strong Demand and Durable Adoption • ~725 patients have received Modeyso3 • Observed strong patient persistence, with longer-term treatment duration data still maturing • Strong academic adoption with expanded field focus in the community through peer-to-peer programs and initiatives to increase biomarker testing 1Since from approval on August 6, 2025; 2Includes $14M of initial inventory build in Japan; 3As of September 30, 2026.
Page 12
12 Zepzelca: 3Q26 Growth Driven by 1L Maintenance ES-SCLC Net product sales ($ in millions) $79 $104 3Q25 3Q26 2026 Dynamics: • Rapid uptake in 1LM ES-SCLC, including successful adoption in the community setting • Consistent with expectations, 2L indication removed from label, 1L maintenance indication unaffected Future Expectations: • Expect competitor data to pose a headwind to Zepzelca sales in 2027 and beyond • Our focus remains on maintaining Zepzelca’s role as an established, practical option for patients +32% YoY
Page 13
13 Pipeline Robert Iannone, M.D., M.S.C.E. Executive Vice President, Global Head of Research & Development, Chief Medical Officer
Page 14
14 New Standard1 of Care in 1L HER2+ GEA Establish Ziihera as the HER2-targeted agent of choice for 1L HER2+ mGEA patients, regardless of PD-L1 statusGOAL: Ziihera = New Standard of Care for 1L HER2+ mGEA Regardless of PD-L1 Status PD-L1+ (CPS ≥1) PD-L1- (CPS <1) Trastuzumab + pembrolizumab + chemo (KN-811 regimen) Trastuzumab + chemo (TOGA regimen) Advanced HER2+ GEA PD-L1+ (CPS ≥1) PD-L1- (CPS <1) ZIIHERA + tislelizumab + chemo1 OR ZIIHERA + chemo2 Advanced HER2+ GEA PRIOR STANDARD OF CARE NEW STANDARD OF CARE 1In combination with fluoropyrimidine- and platinum-containing chemotherapy, and tislelizumab, as first-line treatment of adult patients with HER2-positive (IHC 3+ and IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma; 2In combination with fluoropyrimidine- and platinum-containing chemotherapy, as first-line treatment of adult patients with HER2- positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
Page 15
15 15 Key Clinical Programs PHASE 1 PHASE 2 PHASE 3 PHASE 4 / REGULATORY Recent / Upcoming Milestones Zanidatamab Anticipate top-line data late 2027 / early 2028 Dordaviprone Anticipate interim OS data in 1H27 JZP3507 (ONC206) JZP815 JZP898 Epidiolex (cannabidiol oral solution) Cannabidiol oral capsule formulation PDUFA date of April 16, 2027 JZP047 Initiated Phase 1 in healthy participants JZP6979 (ABS-1230) Initial patient efficacy data to be presented in 4Q26 JZP269 New trial 1L BTC (HERIZON-BTC-302) Neoadjuvant treatment of locally advanced BC (I-SPY2) RAF & RAS mutant tumors Solid tumors Breast cancer patients post T-DXd (EmpowHER-BC-303) Pivotal trial for HER2+ solid tumors (DiscovHER-Pan-206) 1L H3 K27M-mutant diffuse glioma (ACTION) Neoadjuvant and adjuvant BC (EmpowHER-BC-208) Absence Epilepsy Focal-onset seizures Advanced Pheochromocytoma and Paraganglioma (PCPG) Meningioma Juvenile myoclonic epilepsy (JME)2 Developmental and epileptic encephalopathy (DEE) Adults with Lennox-Gastaut syndrome (LGS)1 Capsule formulation 1Phase 3b/4 trial.2Phase 2/3 trial utilizing cannabidiol capsule formulation. KCNT1-related epilepsy Narcolepsy and IH Key Pipeline Programs
Page 16
Phil Johnson Executive Vice President, Chief Financial Officer 16 Financial Performance
Page 17
17 3Q26 Financial Results Continued Commercial Execution + Financial Discipline 17 3Q26 3Q25 Key Commentary Total Revenues $1,243.0M $1,126.1M • Increase driven by growth in Oncology and Xywav • 3Q25 benefitted from lower U.S. Epidiolex gross-to-net deductions and 14 shipping weeks (vs 13 in 3Q26) for U.S. Oncology products Non-GAAP Gross Margin1 91.5% 92.6% • Decline primarily due to royalties on higher sales of Modeyso and Zepzelca Non-GAAP SG&A1 $328.0M $460.1M • 3Q25 included $151.5M in litigation settlement expenses Non-GAAP R&D1 $188.9M $169.9M • Increase due to higher expenses in evidence generation studies and continued growth in our early-stage portfolio Non-GAAP Effective Tax Rate1 (40.3)% (55.5)% • 3Q26 reflects the non tax-deductible Actio acquired IPR&D charge • 3Q25 includes $206M benefit from Chimerix deferred tax asset Weighted-Average Diluted Shares 64.7M 61.6M • Increase driven by shares issued for employee stock compensation and conversion premium for 2026 notes Non-GAAP EPS/LPS1 $(3.88) $8.13 • 3Q26 reflects the Actio acquired IPR&D charge of $754.2M, or $11.03 per share 1Non-GAAP Adjusted Gross Margin, SG&A expenses, R&D expenses, ETR, and EPS/LPS are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures“ and reconciliation tables in the Appendix.
Page 18
18 2026 Financial Guidance Raising Revenue Guidance1 Above Prior Range 18 Updated 2026 Guidance (as of November 2, 2026) Prior Guidance (as of August 3, 2026) Key Commentary Total Revenues $4.775 - $4.850B $4.60 - $4.75B • Continue to expect double-digit growth for combined rare oncology plus epilepsy revenue • Now expect $2.125B - $2.175B in rare sleep revenue2 • Now expect low double-digit to low-teens growth for Xywav revenue Non-GAAP Gross Margin3 90.5% - 91.5% 90% - 91% • Increase driven by higher revenue expectations Non-GAAP SG&A3 $1.33 - $1.37B $1.33 - $1.37B • Unchanged Non-GAAP R&D3 $725 - $775M $725 - $775M • Unchanged despite addition of Actio expenses Non-GAAP Effective Tax Rate3 19.5% - 21.5% 11.5% - 13.5% • Updated to reflect the effect of non-tax deductible acquired IPR&D from Actio acquisition Weighted-Average Diluted Shares 69 - 70M 69 - 70M • Unchanged 1Guidance provided by Jazz Pharmaceuticals as of November 2, 2026; 2Rare sleep franchise includes Xywav, Xyrem and high-sodium oxybate AG royalty revenues; 3Non-GAAP Adjusted Gross margin, SG&A expenses, R&D expenses, and ETR are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures“ and reconciliation table in the Appendix.
Page 19
Renee Gala President and Chief Executive Officer 19 Closing 0
Page 20
20 Strong Momentum into 2027 20 Final analysis from HERIZON-GEA-01 trial presented at ESMO Expect EmpowHER-BC-303 trial top-line readout late 2027 / early 2028 Expect Phase 3 1L ACTION trial readout 1H27 Ongoing launches with full-year of commercial sales in 2026 Launched in 1L HER2+ GEA as of approval on August 25, 2026 Continued commercial execution and data generation Identifying and pursuing opportunities in Rare Disease to drive long-term growth and valueDordaviprone Zanidatamab CommercialResearch and Development Corporate Development Initial patient data to be presented in 4Q26 ABS-1230 (JZP6979)
Page 21
21 Appendix
Page 22
22 Glossary Acronym Definition 1L First-line 2L Second-line Actio Actio Biosciences, Inc. Actio Acquisition Our acquisition of Actio on September 15, 2026 AG Authorized generic ANI/ANL Adjusted net income/Adjusted net loss B Billions BC Breast cancer BTC Biliary tract cancer Chimerix Acquisition Our acquisition of Chimerix on April 21, 2025 CRC Colorectal cancer DEE Developmental and Epileptic Encephalopathy DS Dravet syndrome EPS/LPS Earnings per share/Loss per share ES Extensive-stage ETR Effective Tax Rate FDA U.S. Food and Drug Administration GAAP Generally accepted accounting principles GEA Gastroesophageal adenocarcinoma HCP Healthcare provider HER2 Human epidermal growth factor receptor 2 Acronym Definition IH Idiopathic hypersomnia IPR&D In-process research and development JME Juvenile myoclonic epilepsy LGS Lennox-Gastaut syndrome M Millions NCCN National Comprehensive Cancer Network NDA New drug application NSCLC Non-small cell lung cancer OS Overall survival PD-L1 Programmed Death-Ligand 1 PDUFA Prescription Drug User Fee Act R&D Research and development RAF Rapidly accelerated fibrosarcoma RAS Rat Sarcoma Virus SCLC Small-cell lung cancer SG&A Selling, general and administrative T-DXd Trastuzumab deruxtecan TKI Tyrosine kinase inhibitors TSC Tuberous sclerosis complex YoY Year-over-year, 3Q26 vs. 3Q25 YTD Year-to-date
Page 23
23 Reconciliation of GAAP Reported to Non-GAAP Adjusted Information1 23 1Non-GAAP adjusted net income (loss) (and the related per share measure) are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures”; 2Integration related expenses with respect to the Actio Acquisition and Chimerix Acquisition. In millions, except per share amounts (unaudited) Three Months Ended September 30, 2026 2025 Net Loss Diluted LPS Net Income Diluted EPS GAAP reported $(483.4) $(7.48) $251.4 $4.08 Intangible asset amortization 171.8 2.66 168.4 2.73 Share-based compensation expense 73.8 1.14 88.1 1.43 Restructuring and other costs 34.2 0.53 — — Integration related expenses2 0.4 0.01 16.0 0.26 Acquisition accounting inventory fair value step-up — — 40.4 0.66 Income tax effect of above adjustments (47.6) (0.74) (63.6) (1.03) Non-GAAP adjusted1 $(250.8) $(3.88) $500.7 $8.13 Weighted-average ordinary shares used in diluted per share calculations – GAAP and non- GAAP1 64.7 61.6
Page 24
24 (In millions, except percentages) (unaudited) Three Months Ended September 30, 2026 2025 GAAP gross margin on total revenues 91.1 % 88.6 % Share-based compensation expense 0.4 % 0.4 % Acquisition accounting inventory fair value step-up — % 3.6 % Non-GAAP gross margin on total revenues1 91.5 % 92.6 % GAAP SG&A expenses $407.9 $530.6 Share-based compensation expense (45.4) (61.3) Restructuring and other costs (34.2) — Integration related expenses2 (0.3) (9.2) Non-GAAP SG&A expenses1 $328.0 $460.1 GAAP R&D expenses $211.9 $198.2 Share-based compensation expense (22.9) (21.8) Integration related expenses2 (0.1) (6.5) Non-GAAP R&D expenses1 $188.9 $169.9 GAAP ETR (5.3) % N/A3 Income tax effect of GAAP to non-GAAP reconciling items (35.0) % N/A3 Non-GAAP ETR1 (40.3) % (55.5) % Reconciliation of GAAP Reported to Non-GAAP Adjusted Information1 24 1Non-GAAP gross margin, SG&A expenses, R&D expenses and ETR are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures”; 2Integration related expenses with respect to the Actio Acquisition and Chimerix Acquisition; 3Not a meaningful metric due to minimal GAAP profit before tax in this period.
Page 25
25 Reconciliation of GAAP to Non-GAAP Adjusted1 2026 Guidance 25 1Non-GAAP gross margin, SG&A expenses, R&D expenses and ETR are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures”; 2Integration related expenses with respect to the Actio Acquisition and Chimerix Acquisition. (In millions, except percentages) Projected Range Low High GAAP gross margin on total revenues 89 % 90 % Acquisition accounting inventory fair value step-up 1 % 1 % Share-based compensation expense 0.5 % 0.5 % Non-GAAP gross margin on total revenues1 90.5 % 91.5 % GAAP SG&A expenses $1,544 $1,597 Share-based compensation expense (176) (186) Restructuring and other costs (34) (34) Integration related expenses2 (4) (7) Non-GAAP SG&A expenses1 $1,330 $1,370 GAAP R&D expenses $819 $876 Share-based compensation expense (93) (98) Integration related expenses2 (1) (3) Non-GAAP R&D expenses1 $725 $775 GAAP ETR 20 % 30 % Income tax effect of GAAP to non-GAAP reconciling items (0.5) % (8.5) % Non-GAAP ETR1 19.5 % 21.5 %